Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2016, Article ID 7152761, 16 pages
http://dx.doi.org/10.1155/2016/7152761
Research Article

Magnet-Bead Based MicroRNA Delivery System to Modify CD133+ Stem Cells

1Reference and Translation Center for Cardiac Stem Cell Therapy (RTC), Department of Cardiac Surgery, Rostock University Medical Center, Schillingallee 69, 18057 Rostock, Germany
2Physikalisch-Technische Bundesanstalt, Abbestraße 2-12, Berlin 10587, Germany

Received 7 April 2016; Revised 24 August 2016; Accepted 30 August 2016

Academic Editor: Tao-Sheng Li

Copyright © 2016 Paula Müller et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Girlovanu, S. Susman, O. Soritau et al., “Stem cells—biological update and cell therapy progress,” Clujul Medical, vol. 88, no. 3, pp. 265–271, 2015. View at Publisher · View at Google Scholar
  2. M. Meregalli, A. Farini, M. Belicchi, and Y. Torrente, “CD133+ cells isolated from various sources and their role in future clinical perspectives,” Expert Opinion on Biological Therapy, vol. 10, no. 11, pp. 1521–1528, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Lee and Y.-S. Yoon, “Revisiting cardiovascular regeneration with bone marrow-derived angiogenic and vasculogenic cells,” British Journal of Pharmacology, vol. 169, no. 2, pp. 290–303, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Beksac and F. Preffer, “Is it time to revisit our current hematopoietic progenitor cell quantification methods in the clinic,” Bone Marrow Transplantation, vol. 47, no. 11, pp. 1391–1396, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Bongiovanni, B. Bassetti, E. Gambini et al., “The CD133+ cell as advanced medicinal product for myocardial and limb ischemia,” Stem Cells and Development, vol. 23, no. 20, pp. 2403–2421, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. X. Wang, J. Zhang, F. Zhang et al., “The clinical status of stem cell therapy for ischemic cardiomyopathy,” Stem Cells International, vol. 2015, Article ID 135023, 13 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Ma, Y. Ladilov, J. M. Moebius et al., “Intramyocardial delivery of human CD133+ cells in a SCID mouse cryoinjury model: bone marrow vs. cord blood-derived cells,” Cardiovascular Research, vol. 71, no. 1, pp. 158–169, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Rafii and D. Lyden, “Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration,” Nature Medicine, vol. 9, no. 6, pp. 702–712, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Bartunek, M. Vanderheyden, B. Vandekerckhove et al., “Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety,” Circulation, vol. 112, no. 9, supplement, pp. I178–I183, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Stamm, H.-D. Kleine, Y.-H. Choi et al., “Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies,” The Journal of Thoracic and Cardiovascular Surgery, vol. 133, no. 3, pp. 717.e5–725.e5, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Manginas, E. Goussetis, M. Koutelou et al., “Pilot study to evaluate the safety and feasibility of intracoronary CD133+ and CD133 CD34+ cell therapy in patients with nonviable anterior myocardial infarction,” Catheterization and Cardiovascular Interventions, vol. 69, no. 6, pp. 773–781, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Colombo, M. Castellani, E. Piccaluga et al., “Myocardial blood flow and infarct size after CD133+ cell injection in large myocardial infarction with good recanalization and poor reperfusion: results from a randomized controlled trial,” Journal of Cardiovascular Medicine, vol. 12, no. 4, pp. 239–248, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Yerebakan, A. Kaminski, B. Westphal et al., “Impact of preoperative left ventricular function and time from infarction on the long-term benefits after intramyocardial CD133+ bone marrow stem cell transplant,” The Journal of Thoracic and Cardiovascular Surgery, vol. 142, no. 6, pp. 1530.e3–1539.e3, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Wang and G. Gao, “State-of-the-art human gene therapy: part I. Gene delivery technologies,” Discovery Medicine, vol. 18, no. 97, pp. 67–77, 2014. View at Google Scholar · View at Scopus
  15. S. Sart, T. Ma, and Y. Li, “Preconditioning stem cells for in vivo delivery,” BioResearch Open Access, vol. 3, no. 4, pp. 137–149, 2014. View at Publisher · View at Google Scholar
  16. J. Liu, K. H. Narsinh, F. Lan et al., “Early stem cell engraftment predicts late cardiac functional recovery: preclinical insights from molecular imaging,” Circulation: Cardiovascular Imaging, vol. 5, no. 4, pp. 481–490, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. J. V. Terrovitis, R. R. Smith, and E. Marbán, “Assessment and optimization of cell engraftment after transplantation into the heart,” Circulation Research, vol. 106, no. 3, pp. 479–494, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Lang, S. Lehner, A. Todica et al., “In-vivo comparison of the acute retention of stem cell derivatives and fibroblasts after intramyocardial transplantation in the mouse model,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 12, pp. 2325–2336, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. P. H. Rosado-de-Castro, F. R. Schmidt, V. Battistella et al., “Biodistribution of bone marrow mononuclear cells after intra-arterial or intravenous transplantation in subacute stroke patients,” Regenerative Medicine, vol. 8, no. 2, pp. 145–155, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. W. J. Kang, H. Kang, H. Kim, J. Chung, M. C. Lee, and D. S. Lee, “Tissue distribution of 18F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction,” Journal of Nuclear Medicine, vol. 47, no. 8, pp. 1295–1301, 2006. View at Google Scholar · View at Scopus
  21. E. Goussetis, A. Manginas, M. Koutelou et al., “Intracoronary infusion of CD133+ and CD133CD34+ selected autologous bone marrow progenitor cells in patients with chronic ischemic cardiomyopathy: cell isolation, adherence to the infarcted area, and body distribution,” Stem Cells, vol. 24, no. 10, pp. 2279–2283, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Blocklet, M. Toungouz, G. Berkenboom et al., “Myocardial homing of nonmobilized peripheral-blood CD34+ cells after intracoronary injection,” Stem Cells, vol. 24, no. 2, pp. 333–336, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Penicka, O. Lang, P. Widimsky et al., “One-day kinetics of myocardial engraftment after intracoronary injection of bone marrow mononuclear cells in patients with acute and chronic myocardial infarction,” Heart, vol. 93, no. 7, pp. 837–841, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Caveliers, G. de Keulenaer, H. Everaert et al., “In vivo visualization of 111In labeled CD133+ peripheral blood stem cells after intracoronary administration in patients with chronic ischemic heart disease,” The Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 51, no. 1, pp. 61–66, 2007. View at Google Scholar · View at Scopus
  25. V. Schächinger, A. Aicher, N. Döbert et al., “Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium,” Circulation, vol. 118, no. 14, pp. 1425–1432, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Dedobbeleer, D. Blocklet, M. Toungouz et al., “Myocardial homing and coronary endothelial function after autologous blood CD34+ progenitor cells intracoronary injection in the chronic phase of myocardial infarction,” Journal of Cardiovascular Pharmacology, vol. 53, no. 6, pp. 480–485, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Musialek, L. Tekieli, M. Kostkiewicz et al., “Randomized transcoronary delivery of CD34+ cells with perfusion versus stop-flow method in patients with recent myocardial infarction: early cardiac retention of 99mTc-labeled cells activity,” Journal of Nuclear Cardiology, vol. 18, no. 1, pp. 104–116, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. P. G. Kyrtatos, P. Lehtolainen, M. Junemann-Ramirez et al., “Magnetic tagging increases delivery of circulating progenitors in vascular injury,” JACC: Cardiovascular Interventions, vol. 2, no. 8, pp. 794–802, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. A. C. Vandergriff, T. M. Hensley, E. T. Henry et al., “Magnetic targeting of cardiosphere-derived stem cells with ferumoxytol nanoparticles for treating rats with myocardial infarction,” Biomaterials, vol. 35, no. 30, pp. 8528–8539, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. Z. Huang, Y. Shen, A. Sun et al., “Magnetic targeting enhances retrograde cell retention in a rat model of myocardial infarction,” Stem Cell Research & Therapy, vol. 4, no. 6, article 149, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Yanai, U. O. Häfeli, A. L. Metcalfe et al., “Focused magnetic stem cell targeting to the retina using superparamagnetic iron oxide nanoparticles,” Cell Transplantation, vol. 21, no. 6, pp. 1137–1148, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. A. S. Arbab, E. K. Jordan, L. B. Wilson, G. T. Yocum, B. K. Lewis, and J. A. Frank, “In Vivo trafficking and targeted delivery of magnetically labeled stem cells,” Human Gene Therapy, vol. 15, no. 4, pp. 351–360, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Cores, T. Caranasos, and K. Cheng, “Magnetically targeted stem cell delivery for regenerative medicine,” Journal of Functional Biomaterials, vol. 6, no. 3, pp. 526–546, 2015. View at Publisher · View at Google Scholar
  34. R. Mejías, L. Gutiérrez, G. Salas et al., “Long term biotransformation and toxicity of dimercaptosuccinic acid-coated magnetic nanoparticles support their use in biomedical applications,” Journal of Controlled Release, vol. 171, no. 2, pp. 225–233, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Zheng, M. P. von See, E. Yu et al., “Quantitative magnetic particle imaging monitors the transplantation, biodistribution, and clearance of stem cells in vivo,” Theranostics, vol. 6, no. 3, pp. 291–301, 2016. View at Publisher · View at Google Scholar
  36. W. A. Noort, D. Feye, F. van Den Akker et al., “Mesenchymal stromal cells to treat cardiovascular disease: strategies to improve survival and therapeutic results,” Panminerva Medica, vol. 52, no. 1, pp. 27–40, 2010. View at Google Scholar · View at Scopus
  37. C. W. Don and C. E. Murry, “Improving survival and efficacy of pluripotent stem cell-derived cardiac grafts,” Journal of Cellular and Molecular Medicine, vol. 17, no. 11, pp. 1355–1362, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. T. E. Robey, M. K. Saiget, H. Reinecke, and C. E. Murry, “Systems approaches to preventing transplanted cell death in cardiac repair,” Journal of Molecular and Cellular Cardiology, vol. 45, no. 4, pp. 567–581, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Jakob and U. Landmesser, “Role of microRNAs in stem/progenitor cells and cardiovascular repair,” Cardiovascular Research, vol. 93, no. 4, pp. 614–622, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. C. K. Sen, “MicroRNAs as new maestro conducting the expanding symphony orchestra of regenerative and reparative medicine,” Physiological Genomics, vol. 43, no. 10, pp. 517–520, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. E. P. Papapetrou, N. C. Zoumbos, and A. Athanassiadou, “Genetic modification of hematopoietic stem cells with nonviral systems: past progress and future prospects,” Gene Therapy, vol. 12, no. 1, pp. S118–S130, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Chira, C. S. Jackson, I. Oprea et al., “Progresses towards safe and efficient gene therapy vectors,” Oncotarget, vol. 6, no. 31, pp. 30675–30703, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. K. L. Douglas, “Toward development of artificial viruses for gene therapy: a comparative evaluation of viral and non-viral transfection,” Biotechnology Progress, vol. 24, no. 4, pp. 871–883, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Höbel and A. Aigner, “Polyethylenimines for siRNA and miRNA delivery in vivo,” Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, vol. 5, no. 5, pp. 484–501, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. J. R. Cubillos-Ruiz, L. F. Sempere, and J. R. Conejo-Garcia, “Good things come in small packages: therapeutic anti-tumor immunity induced by microrna nanoparticles,” OncoImmunology, vol. 1, no. 6, pp. 968–970, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Delyagina, A. Schade, D. Scharfenberg et al., “Improved transfection in human mesenchymal stem cells: effective intracellular release of pDNA by magnetic polyplexes,” Nanomedicine, vol. 9, no. 7, pp. 999–1017, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Schade, E. Delyagina, D. Scharfenberg et al., “Innovative strategy for microRNA delivery in human mesenchymal stem cells via magnetic nanoparticles,” International Journal of Molecular Sciences, vol. 14, no. 6, pp. 10710–10726, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. D. R. Sutherland, L. Anderson, M. Keeney, R. Nayar, and I. Chin-Yee, “The ISHAGE guidelines for CD34+ cell determination by flow cytometry,” Journal of Hematotherapy and Stem Cell Research, vol. 5, no. 3, pp. 213–226, 1996. View at Google Scholar · View at Scopus
  49. W. Li, N. Ma, L.-L. Ong et al., “Enhanced thoracic gene delivery by magnetic nanobead-mediated vector,” The Journal of Gene Medicine, vol. 10, no. 8, pp. 897–909, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Kircheis, L. Wightman, A. Schreiber et al., “Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application,” Gene Therapy, vol. 8, no. 1, pp. 28–40, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. I. Almstätter, O. Mykhaylyk, M. Settles et al., “Characterization of magnetic viral complexes for targeted delivery in oncology,” Theranostics, vol. 5, no. 7, pp. 667–685, 2015. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Scharlach, H. Kratz, F. Wiekhorst et al., “Synthesis of acid-stabilized iron oxide nanoparticles and comparison for targeting atherosclerotic plaques: evaluation by MRI, quantitative MPS, and TEM alternative to ambiguous Prussian blue iron staining,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 11, no. 5, pp. 1085–1095, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Harms, A. L. Datwyler, F. Wiekhorst et al., “Certain types of iron oxide nanoparticles are not suited to passively target inflammatory cells that infiltrate the brain in response to stroke,” Journal of Cerebral Blood Flow and Metabolism, vol. 33, no. 5, pp. e1–e9, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. W. C. Poller, N. Löwa, F. Wiekhorst et al., “Magnetic particle spectroscopy reveals dynamic changes in the magnetic behavior of very small superparamagnetic iron oxide nanoparticles during cellular uptake and enables determination of cell-labeling efficacy,” Journal of Biomedical Nanotechnology, vol. 12, no. 2, pp. 337–346, 2016. View at Publisher · View at Google Scholar
  55. A. King, D. Barton, H. A. Beard et al., “REpeated AutoLogous Infusions of STem cells in Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial,” BMJ Open, vol. 5, no. 3, Article ID e007700, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. J. K. Moore, B. M. Stutchfield, and S. J. Forbes, “Systematic review: the effects of autologous stem cell therapy for patients with liver disease,” Alimentary Pharmacology & Therapeutics, vol. 39, no. 7, pp. 673–685, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. H. R. Martínez, J. F. Molina-Lopez, M. T. González-Garza et al., “Stem cell transplantation in amyotrophic lateral sclerosis patients: methodological approach, safety, and feasibility,” Cell Transplantation, vol. 21, no. 9, pp. 1899–1907, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. P. Jimenez-Quevedo, J. J. Gonzalez-Ferrer, M. Sabate et al., “Selected CD133+ progenitor cells to promote angiogenesis in patients with refractory angina: final results of the PROGENITOR randomized trial,” Circulation Research, vol. 115, no. 11, pp. 950–960, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. A. N. Raval, E. G. Schmuck, G. Tefera et al., “Bilateral administration of autologous CD133+ cells in ambulatory patients with refractory critical limb ischemia: lessons learned from a pilot randomized, double-blind, placebo-controlled trial,” Cytotherapy, vol. 16, no. 12, pp. 1720–1732, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. P. Andreone, L. Catani, C. Margini et al., “Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: a phase I clinical trial,” Digestive and Liver Disease, vol. 47, no. 12, pp. 1059–1066, 2016. View at Publisher · View at Google Scholar · View at Scopus
  61. V. Arici, C. Perotti, C. Fabrizio et al., “Autologous immuno magnetically selected CD133+ stem cells in the treatment of no-option critical limb ischemia: clinical and contrast enhanced ultrasound assessed results in eight patients,” Journal of Translational Medicine, vol. 13, no. 1, article 342, 2015. View at Publisher · View at Google Scholar
  62. A. Zali, L. Arab, F. Ashrafi et al., “Intrathecal injection of CD133-positive enriched bone marrow progenitor cells in children with cerebral palsy: feasibility and safety,” Cytotherapy, vol. 17, no. 2, pp. 232–241, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Al-Zoubi, E. Jafar, M. Jamous et al., “Transplantation of purified autologous leukapheresis-derived CD34+ and CD133+ stem cells for patients with chronic spinal cord injuries: long-term evaluation of safety and efficacy,” Cell Transplantation, vol. 23, supplement 1, pp. S25–S34, 2014. View at Publisher · View at Google Scholar
  64. A. Isidori, M. R. Motta, M. Tani et al., “Positive selection and transplantation of autologous highly purified CD133+ stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging,” Biology of Blood and Marrow Transplantation, vol. 13, no. 10, pp. 1224–1232, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. B. A. Nasseri, W. Ebell, M. Dandel et al., “Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: the Cardio133 trial,” European Heart Journal, vol. 35, no. 19, pp. 1263–1274, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. C. Urbich, A. Kuehbacher, and S. Dimmeler, “Role of microRNAs in vascular diseases, inflammation, and angiogenesis,” Cardiovascular Research, vol. 79, no. 4, pp. 581–588, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. S.-M. Ong, S. K. Biswas, and S.-C. Wong, “MicroRNA-mediated immune modulation as a therapeutic strategy in host-implant integration,” Advanced Drug Delivery Reviews, vol. 88, pp. 92–107, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. B. Peng, Y. Chen, and K. W. Leong, “MicroRNA delivery for regenerative medicine,” Advanced Drug Delivery Reviews, vol. 88, pp. 108–122, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. F. Kouhkan, M. Hafizi, N. Mobarra et al., “miRNAs: a new method for erythroid differentiation of hematopoietic stem cells without the presence of growth factors,” Applied Biochemistry and Biotechnology, vol. 172, no. 4, pp. 2055–2069, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. P. Fallah, E. Arefian, M. Naderi et al., “MiR-146a and miR-150 promote the differentiation of CD133+ cells into T-lymphoid lineage,” Molecular Biology Reports, vol. 40, no. 8, pp. 4713–4719, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. P. Neuberg and A. Kichler, “Recent developments in nucleic acid delivery with polyethylenimines,” Advances in Genetics, vol. 88, pp. 263–288, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. P. Midoux, G. Breuzard, J. P. Gomez, and C. Pichon, “Polymer-based gene delivery: a current review on the uptake and intracellular trafficking of polyplexes,” Current Gene Therapy, vol. 8, no. 5, pp. 335–352, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. Y. Zhang, Z. Wang, and R. A. Gemeinhart, “Progress in microRNA delivery,” Journal of Controlled Release, vol. 172, no. 3, pp. 962–974, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. J.-P. Clamme, G. Krishnamoorthy, and Y. Mély, “Intracellular dynamics of the gene delivery vehicle polyethylenimine during transfection: investigation by two-photon fluorescence correlation spectroscopy,” Biochimica et Biophysica Acta—Biomembranes, vol. 1617, no. 1-2, pp. 52–61, 2003. View at Publisher · View at Google Scholar · View at Scopus
  75. E. Tombácz, R. Turcu, V. Socoliuc, and L. Vékás, “Magnetic iron oxide nanoparticles: recent trends in design and synthesis of magnetoresponsive nanosystems,” Biochemical and Biophysical Research Communications, vol. 468, no. 3, pp. 442–453, 2015. View at Publisher · View at Google Scholar · View at Scopus
  76. Y. Fujioka, N. Tanaka, K. Nakanishi et al., “Magnetic field-based delivery of human CD133+ cells promotes functional recovery after rat spinal cord injury,” Spine, vol. 37, no. 13, pp. E768–E777, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Ohkawa, N. Kamei, G. Kamei et al., “Magnetic targeting of human peripheral blood CD133+ Cells for skeletal muscle regeneration,” Tissue Engineering—Part C: Methods, vol. 19, no. 8, pp. 631–641, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Schade, P. Müller, E. Delyagina et al., “Magnetic nanoparticle based nonviral MicroRNA delivery into freshly isolated CD105+ hMSCs,” Stem Cells International, vol. 2014, Article ID 197154, 11 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  79. Y. Ma, Z. Zhang, X. Wang, W. Xia, and H. Gu, “Insights into the mechanism of magnetofection using MNPs-PEI/pDNA/free PEI magnetofectins,” International Journal of Pharmaceutics, vol. 419, no. 1-2, pp. 247–254, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Hanzlíková, M. Ruponen, E. Galli et al., “Mechanisms of polyethylenimine-mediated DNA delivery: free carrier helps to overcome the barrier of cell-surface glycosaminoglycans,” The Journal of Gene Medicine, vol. 13, no. 7-8, pp. 402–409, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. Yue, F. Jin, R. Deng et al., “Revisit complexation between DNA and polyethylenimine—effect of length of free polycationic chains on gene transfection,” Journal of Controlled Release, vol. 152, no. 1, pp. 143–151, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. W. Wang, W. Li, L. Ou et al., “Polyethylenimine-mediated gene delivery into human bone marrow mesenchymal stem cells from patients,” Journal of Cellular and Molecular Medicine, vol. 15, no. 9, pp. 1989–1998, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. N. Voronina, H. Lemcke, F. Wiekhorst et al., “Non-viral magnetic engineering of endothelial cells with microRNA and plasmid-DNA-an optimized targeting approach,” Nanomedicine: Nanotechnology, Biology and Medicine, vol. 12, no. 8, pp. 2353–2364, 2016. View at Publisher · View at Google Scholar
  84. C. A. Lux, P. Mark, C. Klopsch et al., “Impact of short-term liquid storage on human CD133+ stem cells,” Cell Transplantation, vol. 24, no. 11, pp. 2409–2422, 2015. View at Publisher · View at Google Scholar · View at Scopus
  85. M. A. Walasek, R. van Os, and G. de Haan, “Hematopoietic stem cell expansion: challenges and opportunities,” Annals of the New York Academy of Sciences, vol. 1266, no. 1, pp. 138–150, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. G. Sauvageau, N. N. Iscove, and R. K. Humphries, “In vitro and in vivo expansion of hematopoietic stem cells,” Oncogene, vol. 23, no. 43, pp. 7223–7232, 2004. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Yan, J. Wen, M. Liang, Y. Lu, M. Kamata, and I. S. Y. Chen, “Modulation of gene expression by polymer nanocapsule delivery of DNA cassettes encoding small RNAs,” PLoS ONE, vol. 10, no. 6, Article ID e0127986, 2015. View at Publisher · View at Google Scholar · View at Scopus